Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer

◇ RESEARCH

While approved KRAS therapies target only the rare G12C mutation, new drugs including MRTX1133, zoldonrasib, and daraxonrasib are being developed to directly target G12D and G12V—the most common KRAS mutations in CRC. (J Gastrointest Cancer)